Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Accumulated Depreciation (2022 - 2025)

Taysha Gene Therapies' Accumulated Depreciation history spans 3 years, with the latest figure at $3.6 million for Q4 2024.

  • For Q4 2024, Accumulated Depreciation rose 20.31% year-over-year to $3.6 million; the TTM value through Dec 2024 reached $3.6 million, up 20.31%, while the annual FY2024 figure was $3.6 million, 20.31% up from the prior year.
  • Accumulated Depreciation for Q4 2024 was $3.6 million at Taysha Gene Therapies, down from $3.9 million in the prior quarter.
  • Across five years, Accumulated Depreciation topped out at $3.9 million in Q3 2024 and bottomed at $754000.0 in Q1 2022.
  • The 3-year median for Accumulated Depreciation is $3.0 million (2023), against an average of $2.5 million.
  • The largest annual shift saw Accumulated Depreciation soared 81.43% in 2023 before it increased 20.31% in 2024.
  • A 3-year view of Accumulated Depreciation shows it stood at $1.6 million in 2022, then skyrocketed by 81.43% to $3.0 million in 2023, then rose by 20.31% to $3.6 million in 2024.
  • Per Business Quant, the three most recent readings for TSHA's Accumulated Depreciation are $3.6 million (Q4 2024), $3.9 million (Q3 2024), and $3.3 million (Q1 2024).